NOTRELOAD AI
  • NOTRELOAD AI
  • Stocks BUZZ.
  • #TrumpTrade
  • 24-HOUR Pass →
  • Invest ↗
Sign in Subscribe

I-Mab's Givastomig: A Potential Game Changer for Stomach Cancer Treatment

I-Mab's givastomig is a unique immune-boosting drug for stomach cancer, expected to outperform competitors, according to Leerink.

I-Mab's Givastomig: A Potential Game Changer for Stomach Cancer Treatment
Credit: I-Mab
Already have an account? Sign in.
10/03/2025 · 7:07 AM
IMAB
/ Don't stop with just one post.

Related↓

US Considers Major Curbs on Chinese Medicines
09/10/2025 · 3:00 PM

US Considers Major Curbs on Chinese Medicines

US may curb Chinese drugs over national security fears, with stricter reviews for deals/data. I-Mab stock fell but is a US firm. China's biotech role is growing. White House denies active consideration of draft order.

/ Subscriber only
/ Read more

Feed↓

Beyond Meat Launches Protein Drinks Amid Declining Sales
01/16/2026 · 3:30 PM

Beyond Meat Launches Protein Drinks Amid Declining Sales

Beyond Meat introduces carbonated protein drinks through its test kitchen as plant-based meat sales decline. Experts question whether the brand can successfully expand beyond meat alternatives.

/ Subscriber only
JPMorgan Sees Strong AI Demand for CoreWeave
01/16/2026 · 2:48 PM

JPMorgan Sees Strong AI Demand for CoreWeave

JPMorgan says CoreWeave’s AI demand remains very strong, driven by long-term contracts and limited compute supply, while keeping a Neutral rating.

/ Subscriber only
Genmab's Epcoritamab Trial Falls Short on Key Survival Metric
01/16/2026 · 2:37 PM

Genmab's Epcoritamab Trial Falls Short on Key Survival Metric

Genmab's Phase 3 trial for epcoritamab shows mixed results in lymphoma patients, missing its overall survival goal despite some improvements.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe